Filing Details
- Accession Number:
- 0000950170-24-023330
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-29 18:01:58
- Reporting Period:
- 2024-02-27
- Accepted Time:
- 2024-02-29 18:01:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1650648 | 4D Molecular Therapeutics Inc. | FDMT | Biological Products, (No Disgnostic Substances) (2836) | 473506994 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1920738 | Scott Bizily | C/O 4D Molecular Therapeutics, Inc. 5858 Horton Street #455 Emeryville CA 94608 | Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-02-27 | 1,909 | $20.24 | 3,646 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-02-27 | 1,909 | $30.00 | 1,737 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right To Buy) | Disposition | 2024-02-27 | 1,909 | $0.00 | 1,909 | $20.24 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
48,091 | 2032-06-17 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
- The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.